• 1. Comparison of different sample preparation procedures for multiclass determination of selected veterinary drug, coccidiostat and insecticide residues in eggs by liquid chromatography-tandem mass spectrometry
  Marta Piatkowska,Piotr Jedziniak,Jan Zmudzki Anal. Methods 2014 6 3034
• 2. Development of a 15-class multiresidue method for analyzing 78 hydrophilic and hydrophobic veterinary drugs in milk, egg and meat by liquid chromatography-tandem mass spectrometry
  Stephen W. C. Chung,Chi-Ho Lam Anal. Methods 2015 7 6764

Recent Advances in Triclabendazole Sulfone (106791-37-1) Research: A Comprehensive Review

Triclabendazole Sulfone (CAS: 106791-37-1), a key metabolite of the anthelmintic drug triclabendazole, has garnered significant attention in recent years due to its pharmacological properties and potential applications in treating parasitic infections. This research brief synthesizes the latest findings on Triclabendazole Sulfone, focusing on its mechanism of action, pharmacokinetics, and emerging therapeutic uses. The compound's unique chemical structure and bioactivity profile make it a promising candidate for further development in the field of antiparasitic therapeutics.

Recent studies have elucidated the molecular interactions of Triclabendazole Sulfone with its target, the β-tubulin protein in parasitic helminths. Advanced crystallographic and computational modeling techniques have revealed that the sulfone derivative exhibits enhanced binding affinity compared to its parent compound, triclabendazole. This improved interaction is attributed to the sulfone group's ability to form additional hydrogen bonds with key amino acid residues in the β-tubulin binding pocket. These structural insights provide a foundation for the rational design of next-generation anthelmintic agents with improved efficacy against drug-resistant parasite strains.

Pharmacokinetic investigations of Triclabendazole Sulfone have demonstrated favorable absorption and distribution characteristics in both animal models and human clinical trials. A 2023 multicenter study reported that the compound achieves therapeutic concentrations in target tissues within 2-4 hours post-administration, with a plasma half-life of approximately 8-12 hours. Importantly, the sulfone metabolite shows reduced hepatic first-pass metabolism compared to triclabendazole, resulting in improved oral bioavailability. These pharmacokinetic advantages position Triclabendazole Sulfone as a potential standalone therapeutic agent rather than merely a metabolic byproduct.

Emerging research has expanded the potential applications of Triclabendazole Sulfone beyond its traditional use against Fasciola hepatica. In vitro and in vivo studies have demonstrated significant activity against other trematode species, including Schistosoma mansoni and Opisthorchis viverrini. Particularly noteworthy is the compound's effectiveness against juvenile stages of these parasites, addressing a critical unmet need in antiparasitic therapy. The broad-spectrum activity, coupled with a favorable safety profile observed in preclinical toxicology studies, suggests potential for repurposing Triclabendazole Sulfone for additional parasitic indications.

Recent advancements in analytical methodologies have enabled more precise quantification of Triclabendazole Sulfone in biological matrices. Ultra-high performance liquid chromatography tandem mass spectrometry (UHPLC-MS/MS) methods developed in 2024 can detect the compound at concentrations as low as 0.1 ng/mL, facilitating more accurate pharmacokinetic studies and therapeutic drug monitoring. These technological improvements are crucial for optimizing dosing regimens and understanding concentration-effect relationships in clinical settings.

Ongoing clinical trials are evaluating novel formulations of Triclabendazole Sulfone designed to enhance its therapeutic potential. A phase II study currently underway is investigating a nanoparticle-encapsulated version of the drug, which preliminary data suggests may improve tissue penetration and prolong systemic exposure. Another innovative approach involves co-administration with cytochrome P450 inhibitors to further enhance bioavailability. These development efforts reflect the growing recognition of Triclabendazole Sulfone's value as a distinct therapeutic entity rather than simply a metabolic product.

In conclusion, recent research on Triclabendazole Sulfone (106791-37-1) has significantly advanced our understanding of its pharmacological properties and therapeutic potential. The compound's enhanced target binding, favorable pharmacokinetics, and broad-spectrum activity position it as a promising candidate for addressing current challenges in antiparasitic therapy. Future research directions should focus on elucidating its precise mechanism of action against diverse parasite species and exploring potential synergies with other anthelmintic agents to combat emerging drug resistance.

• 2098070-20-1(2-(3-(Pyridin-3-yl)-1H-pyrazol-1-yl)acetimidamide)
• 2680771-01-9(4-cyclopentyl-3-{(prop-2-en-1-yloxy)carbonylamino}butanoic acid)
• 1444113-98-7(N-(3-cyanothiolan-3-yl)-2-[(2,2,2-trifluoroethyl)sulfanyl]pyridine-4-carboxamide)
• 332062-08-5(Fmoc-S-3-amino-4,4-diphenyl-butyric acid)
• 1270529-38-8(1,2,3,4,5,6-Hexahydro-[2,3]bipyridinyl-6-ol)
• 941977-17-9(N'-(3-chloro-2-methylphenyl)-N-2-(dimethylamino)-2-(naphthalen-1-yl)ethylethanediamide)
• 2138166-62-6(2,2-Difluoro-3-[methyl(2-methylbutyl)amino]propanoic acid)
• 89640-58-4(2-Iodo-4-nitrophenylhydrazine)
• 1449132-38-0(3-Fluoro-5-(2-fluoro-5-methylbenzylcarbamoyl)benzeneboronic acid)
• 2034271-14-0(2-(1H-indol-3-yl)-N-{[6-(thiophen-2-yl)-[1,2,4]triazolo[4,3-b]pyridazin-3-yl]methyl}acetamide)